Cidara Therapeutics Operating Income

Cidara Therapeutics's operating income stands at $-200M as of September 2025. That compares with $-45M in the prior-year period — down 340.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Cidara Therapeutics reported $-200M in operating income versus $-45M a year earlier — a 340.6% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $-45M in the prior-year period — down 340.6% year over year. Sustained growth in operating income can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Cidara Therapeutics's operating income evolved across reporting periods, while the comparison chart places CDTX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, operating income is commonly used to spot outliers. Cidara Therapeutics's reading of $-200M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.